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TRIPS AND PHARMACEUTICALS: IMPLICATIONS FOR INDIA 
PRADEEP S. MEHTA* 
O N THE post-Uruguay Round world trade scenario, after the accords in agri-culture and textiles and clothing, the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) is the issue affecting developing countries like India. 
One of the seven intellectual properties covered under TRIPs is that of patents. 
It has been the contentious issue for several reasons. India is committed to 
amend its patent laws by the year 2005 (for technologies previously unprotected 
in its market). The objective is to change the patent system which, in turn, is 
supposed to facilitate research and development activities within the country. 
This Briefing Paper examines the issue of patents and its impact on the pharma-
ceutical industry in India, both foreign and Indian firms. 
1. TRIPS, PHARMACEUTICALS AND INDIA: AN OVERVIEW 
According to the United Nations definition, a patent is a legally enforceable 
right, granted by a country's government to an inventor. A patent excludes other 
persons from manufacturing, using or selling a patented product or from utilis-
ing a patented method or process. 
TRIPs covers seven types of intellectual property rights: 
• trademarks 
• trade secrets 
• geographical indications 
• industrial designs 
• copyright 
• integrated circuits, and 
• patents 
Except in the sectors of food processing, pharmaceutical and agrochemicals the 
Indian patent law is in conformity with the GATT provisions. In the aforemen-
tioned, only process patents are allowed. 
As of today, India has a process patent regime regarding phamaceutical prod-
ucts. Therefore, the 1970 Indian Patents Act has to be changed inorder to bring 
it in line with the international laws on the patenting of pharmaceutical (and 
agrochemical) products. 
Being a developing nation, India has a grace period of five years to change its 
patent laws under the agreement on TRIPs. In other words, the 1970 Indian 
Patents Act will have to be suitably amended by 31st December 1999. 
* Secretary General. CUTS, Jaipur, India. 
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At the same time, developing countries like India are given a grace period of ten 
years for technologies previously unprotected in its market. During this interim 
period of ten years, all patent applications will be put in a «black box». How-
ever, pharmaceutical corporations can apply for an Exclusive Marketing Right 
(EMR) for their products for only five years, even before the country in ques-
tion has fully phased in the new patent protection system. 
The proviso is that the product must have been registered for a patent and has 
received marketing rights in any of the WTO member countries. Thus, it is a 
backdoor method for granting monopoly rights. Furthermore, there is also a 
grey area here. If marketing rights are granted for only five years, what will be 
its position over the five-year period, until the country in question actually has 
amended its patent laws ? 
Transnational corporations (TNCs) control 9 0 % of all registered patents in the 
world. In fact, given such monopoly power over patents and the EMR clause, 
India, or for that matter any developing country, does not have any transition 
period. This is true in the case of protected technology, and if one interprets that 
from the patent/product-originating country angle. This is the haziest part of the 
TRIPs Agreement, with respect to the pharmaceutical and also the agrochemi-
cals sectors. 
2. TRIPS AND PHARMACEUTICAL INDUSTRY IN INDIA 
The existence of process patents under the 1970 Indian Patents Act resulted in a 
robust growth of domestic pharmaceutical industry in India. At the same time, 
history also shows a decline in the business of foreign pharmaceutical compa-
nies in India (see Table 1 for Cross-Sectional Data and Table 2 for Trends). 
Table 1 - Sales and Share of Big Companies in Indian Market, 1992 
Company 
Sales 
(Rs. mn) 
Share 
(%) 
Indian companies 
Ranbaxy 1689 4.4 
Cadila 1467 3 . 8 
Cipla 1175 3 .0 
Lupin 1031 2 .7 
Alembic 1008 2 .6 
TNCs 
Glaxo 2137 5.6 
Pfizer 9 6 3 2.5 
Hoechst 951 2.5 
Boots 930 2 .4 
Burroughs Wellcome 8 2 6 2 . 0 
Source : New Horizons in India, The Consequences of Pharmaceutical Patent Protection, Redwood H, Oldwicks Press 
1994. 
9 8 
Table 2 - Indian Pharmaceut ica l Marke t , 1970 - 1993 
Unit : In Percent 
Sector/Year 1970 1982 1993 
Transnational corporations 80 50 39 
Indian private sector 10 48 60 
Indian public sector 10 2 1 
Source: New Horizons in India, The Consequences of Pharmaceutical Patent Protection, Redwood H, Oldwicks Press 
1994. 
Why is there such a paradox when the global business is expanding at a rapid 
pace ? To answer such a seemingly incongruous fact, one has to take the follow-
ing into account: 
• the 1970 Indian Patents Act was the instrument that made it possible for the 
domestic pharmaceutical industry to expand rapidl:. because the Act 
legalised «reverse engineering» of drugs that are patentable as products, 
through-out the industrialised world, but unprotectable in India; 
• well equipped with technological expertise, Indian scientists and businesses 
seized the opportunity to do «reverse engineering» on therapeutically innov-
ative drugs discovered elsewere, and launched them on the domestic market 
as well as exporting them to other countries, with similar gaps in their patent 
cover; and 
• strategic abdication of many transnational corporations who refused to com-
pete without the patent cover. For example, the Sterling-Winthrop company 
wound up their business in the 1970s and sold their shares to the Indian part-
ner Dey's Medical. 
Furthermore, under the 1970 Indian Patents Act, the following points are rele-
vant: 
• no product patents are allowed in pharmaceutical, agrochemicals and food-
processing sectors, only process patents are admissible; 
• the Indian patent term of fourteen years from the date of filing for pharma-
ceutical processes is curtailed to seven years from the date of filing, or five 
years from the date of sealing a patent, whichever is shorter; and 
• pharmaceutical process patents are automatically deemed to be endorsed a 
License of Right for three years from the date of sealing a pharmaceutical 
patent. 
With the coming of the TRIPs Agreement, disputes have arisen with regard to 
the protection of pharmaceutical patents. The main provisions of the TRIPs 
Agreement with respect to pharmaceutical products are as follows: 
• the minimum patent term will be twenty years from filing; 
• patent protection is to be extended to pharmaceutical products; 
• importation must be accepted as a working patent; 
• compulsory licensing is relegated to special circumstances; 
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• in infringement suits, over process patents, the «burden of proof» is 
reversed; 
• provide transitional arrangements - deferment of the acceptance of pharma-
ceutical product patents by developing countries for ten years; and 
• limited exclusivity is granted to developing countries for pharmaceutical 
products whose patent applications are filed after the enforcement of the 
TRIPs Agreement. 
3. CONSEQUENCES OF TRIPS: MYTHS AND REALITY 
TRIPs does not provide for the retrospective patenting in India of drugs that are 
already on the market or covered by existing patent applications elsewhere. Tak-
ing into account the transitional period, there will be less impact on prices of 
new patented drugs on the Indian market during the 1990s and only a minimal 
effect until 2005. Thereafter, it will build up gradually from a pool of new 
drugs. Global progress, in research and development, is replenishing this pool at 
a steady but moderate pace, as older drug patents expire (see Box 1). 
BOX 1 - PHARMA-QUAKE AS PATENTS EXPIRE 
A BOUT 40 US drugs wi th $16bn sales in 1996 are set to loose patent protection by the year 2002. This wi l l throw the gate open for competition from generic drugs. 
Cheaper drug price and bonanza for generic drugs wi l l alter the research and business of pharmaceuti-
cal majors. 
To f i l l the patent gap, drug majors are turning more to biotechnology development and other partners. 
The pressing needs for new drugs have led to the earlier adoption of new technologies. 
To avoid «Tagamat Crisis» (loss of patents), the companies are increasingly investing in riskier, cutting-
edge technologies. Smithkline-Beecham is one of the first such companies to leap into new technolo-
gies for gene-hunting. 
Again, Glaxo, after realising the futil ity of blockbluster dependency, is contemplating to develop a 
broader«port fo l io»of drugs. The rationale is to minimise risks associated wi th the development of new 
drugs. 
Source: Wall Street Journal, 13 August 1997. 
Here, one has to consider the moderate pace of pharmaceutical innovation and 
of obstacles to market penetration of new drugs in India. Such consideration 
leads to the conclusion that, in value term, not more than 1 5 % of the Indian 
market will be covered by patents some time after 2005. The remaining 85 % of 
the market will continue to be exposed to the impact of generic competition. 
Patented products will themselves ultimately contribute to that generic pool 
when their patents expire. 
The time scale of the introduction of pharmaceutical patents in India under 
TRIPs makes it certain that, if Indian drug prices rise during the remainder of 
the 1990s, it will not be for patenting reasons. The earliest start of premium 
pricing for patented drugs will be in the early years of the next decade. No sig-
nificant effect can be anticipated until after 2005, because the weight of 
patented drugs on the Indian market will be too small for economic impact. 
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More important than the time scale of patent protection will be fundamental 
« checks and balances » which will slow down on the impact of premium pricing 
on Indian drug expenditure (see Box 2). Such balances are as follows: 
• the low purchasing power of Indian patents; 
• Government price controls under permanent or reserve powers; 
• therapeutic competition from cheaper unpatented drugs. 
Of these the second is the most immediate, whereas the first and the third are 
the most «durable» safeguards against a price explosion. 
BOX 2 - COMPULSORY LICENSING OF COMMERCIAL MEDICINES POSSIBLE 
A CCORDING to the Coordinator of the Forum of Parliamentarians on Intellectual Property, India, Mr. B.K. Keyala, compulsory licensing of pharmaceutical products «for commercial purposes» is pos-
sible, wi thin the ambit of the TRIPs Agreement. 
Argued Keyala: «India should draw strength from Arts. 7 and 8 of TRIPs and insist on compulsory 
licensing of pharmaceutical products for commercial purposes.» 
The current understanding, under Art.31 of the agreement, is that TRIPs provisions only allow compul-
sory licensing for non-commercial use. However, Art. 7, which outlines the objectives of the intellectual 
property agreement, states that implementation of the agreement should inter alia «contribute to the 
transfer and dissemination of technology». 
Furthermore, Art. 8 gives member countries the right to adopt measures to «protect public health and 
nutrition» and «promote public interest». 
India should interpret these articles in the national interest since the constitutional guarantee of the 
right to life encompasses the right to health, which requires «availability of medicines at affordable 
prices», said Keyala. 
Source: Press Trust of India, 26 December 1996. 
Here it will be interesting to note that Canada established the Patented Medicine 
Prices Review Board in 1987, under reforms to extend patent protection to 
brand-name pharmaceuticals. Until recently, the Board reached over 100 settle-
ments with the pharma industry, which it claims has saved consumers about 
C$110mn. In a recent case, it ordered a US company, ICN Pharmaceutical's 
local subsidiary, to cut the price of its Virazole by almost 9 0 % and pay a 
penalty of C$1.2 mn. Thus, there are precedents for such price regulations. 
There is, nevertheless, a widespread belief among Indian companies that even if 
the remaining preconditions for R & D in India were met, they could not afford 
the cost of minimum scale operations, and that only TNCs would be in a posi-
tion to benefit. 
Evidently, TNCs have far greater financial resources, but they also have more 
diverse calls on those resources and are themselves obliged to make difficult 
choices when it comes to new R & D projects and facilities (see Table 3). 
For TNCs, their challenge in India is whether the Indian authorities will pursue 
their declared objective of attracting global investment and R & D to India by 
meeting the essential pre-conditions. 
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Table 3 - Available Revenue for R & D Activities 
Unit: As percentage of sales 
9 global pharma companies in India (1992 - 93) 6.5 
7 Indian pharma companies (1992 - 93) 7.4 
10 Japanese pharma companies (1991 - 92) 20.6 
8 global parent group1 (1991 - 92) 32.0 
1. 8 out of 9 companies of the first row. 
Source: New Horizons in India, The Consequences of Pharmaceutical Patent Protection, Redwood H. Oldwicks Press 
1994. 
4 . IMPACT OFTRIPS ON GLOBAL BUSINESS 
As expected, the proposed changes in the intellectual property regime are wel-
comed by the global business and their subsidiaries operating in India. Big 
TNCs like Hoechst, Novartis, etc., have already set up 100% Indian sub-
sidiaries. However, most of them are interested in playing a waiting game 
regarding their involvement in the Indian pharmaceuticals market. 
They are likely to introduce their new patented drugs once the system of prod-
uct patent becomes fully operational. Even in that case, most of the new drugs 
will either be imported as formulations or be formulated in India, by using 
imported bulk drugs. In short, India is unlikely to be a site for R & D and pro-
duction of bulk drugs. 
For example, according to Glaxo-Wellcome, it is holding back on investments 
in India because of concerns on Intellectual Property Rights (IPR). However, it 
plans to build up volumes in certain therapeutic segments, by allowing their 
Indian subsidiary to negotiate a cheaper price for imports from the parent com-
pany. 
Under the TRIPs Agreement, India has to accept applications for the grant of 
product patents from 1st January 1995. According to one estimate, up to July 
1996, 264 applications were received by the patent office. 
Another area of concern is the pricing of drugs under the new patent regime. 
Though it is a fact that the prices of Indian drugs are lower than those prevailing 
in developed countries, the future price differential is unlikely to be large. The 
reason is to avoid any action against the dumping of bulk drugs. 
5. IMPACT OF TRIPS ON INDIAN FIRMS 
Axiomatically, the introduction of product patenting will affect the Indian phar-
maceutical firms to a large extent. Certainly, they will be prevented from taking 
a circuitous route to growth through the adoption of process patents. At the 
same time, some of them are seriously concerned with the expansion of their 
business. 
To achieve their aim, they are increasingly exploring the following options. 
1 0 2 
6. DEVELOPMENT OF NEW DRUGS 
A necessary condition is to increase the expenditure on R & D activities. Drug 
discovery and development have to be included in the R & D strategy. In other 
words, the focus of R & D will have to be changed from the innovation of new 
processes to the invention of new products. 
For example, Dr. Reddy's Laboratory (a leading Indian manufacturer) has 
focused its R & D expenditure on the development of new drugs for cancer, 
bacterial infections and diabetes. They have set up a research facility at the cost 
of Rs.8 crore (approximately $2.3 mn). 
However, a couple of structural weaknesses have to be taken into account. First, 
given the small size of Indian firms, even a sharp increase in R & D activities 
will not generate sufficient funds for the development of new drugs. Secondly, 
Indian firms lack manpower and other institutional mechanisms to launch new 
drugs successfully in the foreign market. 
Given such limitations, the focus on R & D should be on: 
• the development of in-house drugs that have the same therapeutic value of 
those existing in the market; 
• the production of indigenous drugs, catering to the needs of India and other 
tropical countries, where TNCs have little or no interest in introducing drugs 
according to their needs. 
7. PRODUCTION OF OFF-PATENT DRUGS 
A realistic assumption is that, in near future, off-patent drugs will emerge as one 
of the important activity of Indian pharmaceutical firms. 
Furthermore, off-patent (generic) drugs, made by the Indian firms, are going to 
meet most of the domestic demand. At the same time, it is incorrect to say that 
their therapeutic value will be less than the new, on-patent drugs. 
With the increasing concentration of Indian firms on generic drugs, its export 
prospects are very high. Currently, the world market for generic drugs is $20 bn, 
and expected to grow to $40 bn by 2005. In order to take this opportunity, lead-
ing Indian firms (like Ranbaxy, SOL, East India Pharmaceuticals) are building 
their capacities to produce generic drugs. 
For example, SOL (Hyderabad) has set up a separate division for the production 
of generics. Furthermore, it is expecting to generate more than 3 3 % of its 
annual turnover from generics. Exports of generics will get on further boost 
from foreign investment in this area. US pharma giant Merck has set up a 100% 
subsidiary to produce and export generics. 
However, Indian firms are going to face strong competition from other develop-
ing countries, and even some developed countries. Therefore, the long run suc-
cess of Indian firms depends on improved efficiency and exploration of new 
markets through South-North and South-South cooperation, both at the produc-
ers 'and consumers'levels. 
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8. PRODUCTION OF PATENTED DRUGS UNDER LICENSE 
Global drug development and production have recently been undergoing struc-
tural changes. The reasons for such changes are: 
• exponential increase in the cost of drug development; 
• shortening of product life; 
• stiff competition from generic drugs. 
In order to gain maximum revenue within a short period, Indian firms are trying 
to get licenses from global pharma business to produce and market on-patent 
drugs. 
However, two discernible facts are worth mentioning: 
• global pharma companies that do not have much stake in Indian market will 
not hesitate to give licenses to Indian firms; 
• companies with large subsidiaries in India (like Glaxo, Pfizer) are likely to 
introduce licensed drugs through their subsidiaries only. 
9. MARKETING OF IMPORTED DRUGS 
The fourth option for Indian pharma firms is the marketing of imported drugs. 
Many Indian firms are interested in entering into long-term arrangements with 
global businesses. For example, Ranbaxy has entered into an alliance with Eli 
Lilly. 
The new and liberalised drug policy has removed import restrictions from all 
but eight category of drugs. Removal of import restrictions and proposed 
changes in IPR will lead to an increase in drugs import. 
10. TRIPS: AVAILABILITY AND PRICES OF DRUGS 
The aforementioned discussions on off-patent drugs reveal the fact that they 
will meet most of the demands. Therefore, even under the new patent regime 
(compatible with the TRIPs Agreement), the availability and prices of generic 
drugs will largely be unaffected. 
However, the situation is different with respect to new (on-patent) drugs. There 
is no doubt that these drugs will be available in the Indian market (either 
through production or under license). But the effect on prices is ambiguous. 
Under the customary theory of demand-supply, the price level should come 
down in future. The reason is increased supply rather than increase in demand. 
Albeit, this ideal situation may not be true in practice because of the following 
factors: 
• the oligopolistic nature of global pharma business; 
• the practice of transfer pricing by the global business, monitoring and regu-
lation of prices by the Government will be difficult; 
• the price situation also depends on the proportion of patented drugs being 
sold in the Indian market. At the same time, the global pharma business has 
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a large number of patented drugs that comes from their own R & D (see 
Table 4). 
Furthermore, in the long run, medical biotechnology is going to be the area of 
research and development. Biotechnology base research of Indian firms (except 
the Government-owned Central Drug Research Institute) is poor, and they are 
unlikely able to produce many of these drugs. 
Table 4 - R & D Posit ion of World Pharmaceut ica l Majors , 1995 
Number of Drugs 
Company Own R & D (% of the total) Under License Total 
Hoechst 125 (66.1) 64 189 
Glaxo-Wellcome 117 (76.0) 37 154 
Merck & Co. 108 (85.7) 18 126 
Smithkline-Beecham 77 (64.7) 42 119 
El Lilly 61 (67.8) 29 90 
Rhone-Poulenc 53 (68.8) 24 77 
Yamanouchi 42 (68.8) 19 61 
Pfizer 44 (73.3) 16 60 
Source : Scrip, January 1996. 
On the other hand, TNCs have a large base for research in medical biotechnol-
ogy (see Box 3). Given such a dominant position, prices of on-patent drugs are 
likely to go beyond the reach of the consumers at large in the long run. There-
fore, the real issue is not availability of new drugs in the Indian market, but peo-
ple's access to them. 
BOX 3 - HOECHST PATENTS AYURVEDIC HERB 
H OECHST, Germany, patented the Indian medicinal plant Coleus Forskohlii, which is being used for ayurvedic medicine. 
Traditional uses of this herb include treatment for cardiovascular disease, abdominal colic, respiratory 
disorders, painful urination, insomnia and convulsions. 
In 1974, a large-scale screening of medicinal plants by the Central Drug Research Institute of India 
revealed the blood pressure lowering and anti-spasmodic effects of extracts from C. Forskohlii. 
One of Hoechst's patents covers a specific formula of the plant extract and its use in treating cardiovas-
cular disease and intraocular pressure. 
According to a report by the Rural Advancement Foundation International, Canada, in 1997, Hoechst 
wi l l begin worlwide marketing of its C. Forskohlii derived drug. 
Source: Press Trust of India; 20 February 1997 
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11. CONCLUSIONS 
Given such a hazy scenario, it is difficult to predict the future of the Indian 
pharmaceutical industry under the « n e w » regime of intellectual property rights 
and its relationship with international trade. However, certain broad trends can 
be pictured. 
First of all Indian pharma companies are going to face stiff competition from 
the global business, despite the fact that, at least in India, the pharma market is 
not oligopolistic. At the same time, trends in research and development can 
make it so in the long run. 
Therefore, Indian companies can either go for collaboration or concentrate on 
producing and marketing generic drugs. This futuristic conclusion is based on a 
realistic assumption which takes into consideration the poor research and mar-
ket penetration strategies of Indian companies. 
On the other hand, global pharma majors are unlikely to consider India as one 
of their bases for exploring « n e w » drugs through research. At the most, India 
can be an « assembly » point for some drugs. 
The trickiest part is what position should the Indian government take regarding 
TRIPs and its impact on pharmaceutical market. The issue is a political eco-
nomic one, and has to be approached from both angles - economics and poli-
tics. 
Overall, the Government of India has two options: 
• introduce an effective regulatory mechanism for «checks and balances» on 
the availability, access and price of essential drugs; 
• develop research facilities for the introduction of « n e w » drugs, catering to 
the needs of the country. 
Global businesses do not have any interest in developing tropical drugs. Given 
its traditional medicinal plant base, India can take a leading position in develop-
ing, producing and exporting those drugs. 
The drug policy of the government has to be a pro-active one - to take advan-
tage of the TRIPs regime. Compatibility between the above-mentioned two 
options serves as a base for rational and need-based drug policy. 
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